JanaPortnowMD

Oncology • Duarte, CA

Hematologic Oncology, Neuro-Oncology

Physician

Join to view full profile

Dr. Portnow is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Portnow's full profile

Already have an account?

Office
1500 Duarte Rd
Duarte, CA 91010
Phone+1 626-471-9200

Fax+1 626-301-8233

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1999 - 2002
Temple University HospitalResidency, Internal Medicine, 1994 - 1997
University of Rochester School of Medicine and DentistryClass of 1994

Certifications & Licensure

CA State Medical License 2002 - 2026
MD State Medical License 1998 - 2003
PA State Medical License 1995 - 1998
American Board of Internal Medicine Medical Oncology

Clinical Trials

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer Start of enrollment: 2006 Dec 01
Active, not recruiting
Phase 3
High-Dose Methotrexate and Leucovorin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Start of enrollment: 2005 Jul 12
Completed
Phase 2
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment Start of enrollment: 2005 Jan 01
Completed
Phase 1
Temozolomide in Treating Patients With Primary Brain Tumors or Metastatic Brain Tumors Start of enrollment: 2006 Jan 01
Completed
Phase 1
Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade Glioma Start of enrollment: 2008 Apr 01
Completed
Phase 1
A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors Start of enrollment: 2008 Jun 01
Completed
Phase 1
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Start of enrollment: 2009 Jun 01
Completed
Phase 3
A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma Start of enrollment: 2010 Jul 01
Completed
Phase 1
A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas Start of enrollment: 2010 Aug 01
Completed
Phase 1
Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases Start of enrollment: 2010 Dec 01
Completed
Phase 1
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma Start of enrollment: 2014 Feb 01
Terminated
Phase 2
Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma Start of enrollment: 2014 Mar 01
Completed
Phase 2
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas Start of enrollment: 2014 Oct 07
Completed
Phase 1
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas Start of enrollment: 2016 Mar 07
Active, not recruiting
Phase 1
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases Start of enrollment: 2018 Aug 31
Recruiting
Phase 1
Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM Start of enrollment: 2020 Dec 08
Active, not recruiting
Not Applicable
Roles: Contact
Low Dose Versus Standard Dose Dexamethasone for Reduction of Swelling in Patients With Primary or Metastatic Brain Tumors Start of enrollment: 2022 Apr 09
Active, not recruiting
Phase 2
Roles: Contact, Principal Investigator
Multiple Doses of Neural Stem Cell Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas Start of enrollment: 2023 May 02
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients With Glioblastoma Start of enrollment: 2024 Aug 15
Not yet recruiting
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

NCCN CNS Tumor Guidelines Update for 2024.
Louis Burt Nabors, Jona Hattangadi-Gluth, Craig Horbinski, Jana Portnow
Neuro-Oncology. 2024-12-18
An intracerebral microdialysis study to determine the neuropharmacokinetics of eribulin in patients with metastatic or primary brain tumors.
Zeynep Eroglu, Timothy Synold, Behnam Badie, An Liu, Arnab Chowdhury
Cancer Chemotherapy and Pharmacology. 2024-12-01
Multi-Omic Characterization of Single Cells and Cell-Free Components Detected in the Cerebrospinal Fluid of Patients with Leptomeningeal Disease.
Stephanie N Shishido, Amelia Marvit, Doanna Pham, Theresa Luo, Liya Xu
Cancers. 2024-11-06

Press Mentions

Northwest Biotherapeutics: Data Is Done, Just Wait for ApprovalNovember 23rd, 2022
Calidi Biotherapeutics Announces FDA Authorization of IND for a Phase 1 Clinical Trial of NeuroNova in Patients with Recurrent High-Grade GliomaAugust 2nd, 2022
City of Hope Scientist Receives $9.28 Million for CAR T Cell Immunotherapy Clinical Trial for Patients with HER2-Positive Breast Cancer That Has Spread to the BrainAugust 13th, 2019
Join now to see all

Grant Support

Pilot Feasibility Dose Escalation Study Using Intracerebral MicrodialysisNational Center For Research Resources2009
A Pharmacokinetic And Pharmacogenomic Study Of Patients With High-GradeNational Center For Research Resources2008–2009
A Phase I Study Of Bortezomib And Temozolomide In Patients With Refractory SolidNational Center For Research Resources2006–2009
A Pilot Feasibility Study Of Intracerebral Microdialysis To Determine The NeuroNational Center For Research Resources2007–2008